Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States.
{iframe}https://finance.yahoo.com/news/altimmune-announces-important-additions-patent-120000741.html{/iframe}